By Kurt Orzeck (April 9, 2014, 8:47 PM EDT) -- A Florida federal jury decided Wednesday that Novartis Pharmaceuticals Corp. didn't negligently fail to sufficiently warn a prescribing physician of the risks of jaw injuries allegedly caused by the bone drugs Aredia and Zometa, granting the company a victory in a sprawling product liability battle.
The jury returned its verdict shortly after deliberations started earlier Wednesday and following the pharmaceutical company's arguments that plaintiff Ruth Dopson-Troutt failed to prove that Novartis' osteonecrosis of the jaw warnings were inadequate or that, with some different warning, the plaintiff's doctor would have altered his behavior and her injury would have been avoided.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!